SM
MCRB icon

Sabby Management’s Seres Therapeutics MCRB Stock Holding History

Sabby Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed -$142K – 323
2016
Q2 		$142K Buy
+2
New +$1.17K 0.01% 257
2016
Q1 		– Sell
-3
Closed -$235K – 329
2015
Q4 		$235K Buy
+3
New +$1.97K 0.01% 277

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's MCRB Position: Q3 2016 in Review

Sabby Management sold out of Seres Therapeutics (MCRB) in Q3 2016, closing a stake of 1,030 shares — an estimated $598K sold.

Sabby Management first reported a position in MCRB in Q3 2015 and held it in 4 quarters. The position peaked at $1.92M in Q3 2015. 94 funds tracked by Wall St. Rank hold MCRB as of Q3 2016.

  • Sabby Management reported no remaining Seres Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Sabby Management sold 1,030 Seres Therapeutics shares in Q3 2016, an estimated $598K.
  • Sabby Management first reported a position in Seres Therapeutics in Q3 2015 and held it in 4 quarters.
  • Sabby Management's Seres Therapeutics position peaked at $1.92M in Q3 2015.
  • 94 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.